Lifetime course of myasthenia gravis

Muscle and Nerve

Volumn 37, Issue 2, 2008, Pages 141-149

  Grob, David ^a   Brunner, Norman ^a   Namba, Tatsuji ^a   Pagala, Murali ^a  

^a MAIMONIDES MEDICAL CENTER   (United States)

Author keywords

Acetylcholine receptor antibodies; Excitation contraction coupling; Generalized myasthenia gravis; Muscle fatigue; Muscle weakness; Myasthenia gravis, ocular myasthenia gravis

Indexed keywords

CHOLINERGIC RECEPTOR ANTIBODY; CHOLINESTERASE INHIBITOR;

ADULT; CLINICAL ASSESSMENT; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYASTHENIA GRAVIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SEX DIFFERENCE; THYMECTOMY;

ADULT; AGE OF ONSET; AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; MYASTHENIA GRAVIS; RECEPTORS, CHOLINERGIC; RETROSPECTIVE STUDIES; SEX FACTORS; THYMECTOMY;

EID: 38949099991     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.20950     Document Type: Review

References (44)

1. Aarli JA, Stefansson K, Marton LSG, Wollmann RL. Patients with myasthenia gravis and thymoma have in their sera IgG autoantibodies against titin. Clin Exp Imunol 1990;82:284-288.
2. Blalock A, Mason MF, Morgan HE, Riven SS. Myasthenia gravis and tumors of the thymic region. Report of a case in which the tumor was removed. Ann Surg 1939;110:544-561.
3. Brunner NG, Namba T, Grob D. Corticosteroids in the management of severe, generalized myasthenia gravis. Neurology 1972;22:603-610.
4. Campbell H, Bramwell E. Myasthenia gravis pseudoparalytica: review of 70 case reports, including nine new patients. Brain 1900;23:277-336.
5. Dau PC, Lindstrom JM, Cassel CK, Denys EH, Shev EE, Spitler LE. Plasmapheresis and immunosuppressive drug therapy in myasthenia gravis. N Engl J Med 1977;297:1134-1140.
6. Deymeer F, Gungor-Tuncer O, Yilmaz V, Parman Y, Serdaroglu P, Ozdemir C, et al. Clinical comparison of anti-MuSK- vs anti-AChR-positive and seronegative myasthenia gravis. Neurology 2007;68:609-611.
7. Domagk G. Eine neue Klasse von Desinfection-mitteln. Dtsch Med Wochenschr 1935;61:829-832.
8. Erb W. Zur casuistic der bulbaren lahmungen. Arch Psychiat 1879;9:325-350.
9. Fleming A. Penicillin, its practical application. Philadelphia: Blakestone; 1946. p 1-33.
10. Flood PR, Bjugn R, Gilhus NE, Hofstad H, Matre R, Aarlie JA. The ultrastructural localization of antigens for antibodies in myasthenia gravis. Ann N Y Acad Sci 1987;505:732-734.
11. Goldflam S. Ueber einen scheinbar heilbaren bulbarparalytischen Symptomen-complex mit Betheiligung der Extremitaten., Dtsch Ztschr Nervenh 1893;4:312-352.
12. Grob D. Course and management of myasthenia gravis. JAMA 1953;1153:529-532.
13. Grob D. Myasthenia gravis. Current status of pathogenesis, clinical manifestations, and management. J Chronic Dis 1958;8:536-566.
14. Grob D. Myasthenia gravis. A review of pathogenesis and treatment. Arch Intern Med 1961;108:615-638.
15. Grob D. Clinical manifestations of myasthenia gravis. In: Albuquerque EX, Elderefrawi AT, editors. Myasthenia gravis. London: Chapman and Hall; 1983. p 319-345.
16. Grob D, Arsura EL, Brunner NG, Namba T. The course of myasthenia gravis and therapies affecting outcome. Ann N Y Acad Sci 1987;505:472-499
17. Grob D, Brunner NG, Namba T. The natural course of myasthenia gravis and effect of therapeutic measures. Ann N Y Acad Sci 1981;377:652-669.
18. Grob D, Harvey AM. Abnormalities of neuromuscular transmission with special reference to myasthenia gravis. Am J Med 1953;15:695-709.
19. Grob D, Johns RJ, Harvey AM. Studies in neuromuscular function in normal subjects and patients with myasthenia gravis. Bull Johns Hopkins Hosp 1956;99:115-238.
20. Grob D, Namba T. Corticotropin in generalized myasthenia gravis. Effect of short intensive courses. JAMA 1966;198:703-707.
21. Hoch W, McConville J, Helmes S, Newsom-Davis J, Melms A, Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 2001;7:365-368.
22. Iwasa K. Striational autoantibodies in myasthenia gravis mainly react with ryanodine receptor. Muscle Nerve 1997;20:753-756.
23. Jaretzki A, Bethea M, Wolff M, Olarte MR, Lovelace RE, Penn AS, et al. A rational approach to total thymectomy in the treatment of myasthenia gravis. Ann Thorac Surg 1977;24:120-130.
24. Jolly F. Ueber Myasthenia gravis pseudoparalytica, Berlin klin Wchuschr 1895;32:1-7.
25. Keesey JC. Clinical evaluation and management of myasthenia gravis. Muscle Nerve 2004;29:484-505.
26. Kennedy FS, Moersch FP. Myasthenia gravis. A clinical review of 87 cases observed between 1915 and the early part of 1932. CMAJ 1937;37:216-223.
27. Lassen HCA. Preliminary report of the 1952 epidemic of poliomyelitis in Copenhagen with special reference to the treatment of acute respiratory insufficiency. Lancet 1953;1:37-41.
28. Lindstrom JM, Seybold ME, Lennon VA, Whittingham S, Duane DD. Antibody to acetylcholine receptor in myasthenia gravis. Neurology 1976;26:1054-1059.
29. Mertens HG, Balzereit F, Leipert M. The treatment of severe myasthenia gravis with immunosuppressive agents. Eur Neurol 1969;2:321-339.
30. Mygland A, Tysnes OB, Matre R, Volpe P, Aarlie JA, Gilhus NE. Ryanodine receptor antibodies in myasthenia gravis patients with a thymoma. Ann Neurol 1992;32:589-591.
31. Nakata M, Kuwabara S, Kawaguchi N, Takahashi H, Misawa S, Kanai K, et al. Is excitation-contraction coupling impaired in myasthenia gravis? Clin Neurophysiol 2007;118:1144-1148.
32. Namba T, Nakata Y, Grob D. The role of humoral and cellular immune factors in neuromuscular block in myasthenia gravis. N Y Acad Sci 1976;274:493-515.
33. Oppenheim H. Ueber einen Fall von chronischer progressiver Bulbarparalyse ohne anatomischen Befund. Virchow's Arch Path Anat 1887;108:522-530.
34. Pagala MKD, Namba T, Grob D. Desensitization to acetylcholine at motor end plates in normal humans, patients with myasthenia gravis, and experimental models of myasthenia. Ann N Y Acad Sci 1981;377:567-582.
35. Pagala MKD, Nandakumar NV, Venkatachari SAT, Ravindran K, Namba T, Grob D. Responses of intercostal muscle biopsies from normal subjects and patients with myasthenia gravis. Muscle Nerve 1990;13:1012-1022.
36. Pagala M, Nandakumar NV, Venkatachari SAT, Ravindran K, Amaladevi B, Namba T, et al. Mechanisms of fatigue in normal intercostal muscle and muscle from patients with myasthenia gravis. Muscle Nerve 1993;16:911-921.
37. Papatestas AE, Alpert KE, Osserman KE, Osserman RS, Kark AE. Studies in myasthenia gravis: effects of thymectomy. Results in 1985 patients with nonthymomatous and thymomatous myasthenia gravis. Am J Med 1971;50:465-474.
38. Romi F, Aarli JA, Gilhus NE. Myasthenia gravis patients with ryanodine receptor antibodies have distinctive clinical features. Eur J Neurol 2007;14:617-620.
39. Sanders DB, El-Salem K, Massey JM, McConville J, Vincent A. Clinical aspects of MuSK antibody positive seronegative MG. Neurology 2003;60:1978-1980.
40. Simpson JA. An evaluation of thymectomy in myasthenia gravis. Brain 1958;81:112-144.
41. Skeie GO, Romi F, Aarlie JA, Bentsen PT, Gilhus NE. Pathogenesis of myositis and myasthenia associated with titin and ryanodine receptor antibodies. Ann NY Acad Sci 2003;998:343-350.
42. Strauss AJL, Seegal BC, Hsu KC, Burkholder PM, Nastuk WL, Osserman KE. Immunofluorescence demonstration of a muscle binding, complement-fixing serum globulin fraction in myasthenia gravis. Proc Soc Exper Biol Med 1960;105:184-191.
43. Walker MB. Treatment of myasthenia gravis with physostigmine. Lancet 1934;1:1200-1201.
44. Willis T. De Anima Brutorum. Oxford: Theatro Sheldiano; 1672. p 404.